AKT mediates actinomycin D-induced p53 expression

Oncotarget

Volumn 5, Issue 3, 2014, Pages 693-703

  Chen, Chih Shou ^a   Ho, Dong Ru ^a   Chen, Fei Yun ^b   Chen, Chang Rong ^b   Ke, Yu De ^b   Su, Jyan Gwo Joseph ^b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL CHIAYI UNIVERSITY   (Taiwan)

Author keywords

Actinomycin D; AKT; P53

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; DACTINOMYCIN; DEGUELIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; WORTMANNIN; TP53 PROTEIN, HUMAN;

ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION; APOPTOSIS; BIOSYNTHESIS; DOSE RESPONSE; DRUG EFFECTS; HEK293 CELL LINE; HEPG2 CELL LINE; METABOLISM; PHOSPHORYLATION;

APOPTOSIS; DACTINOMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HEK293 CELLS; HEP G2 CELLS; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84896896949     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1328     Document Type: Article

References (48)

1. Vousden KH and Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer. 2002; 2(8):594-604.
2. Fridman JS and Lowe SW. Control of apoptosis by p53. Oncogene. 2003; 22(56):9030-9040.
3. Shangary S and Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res. 2008; 14(17):5318-5324.
4. Teodoro JG, Evans SK and Green MR. Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med. 2007; 85(11):1175-1186.
5. Kortlever RM, Higgins PJ and Bernards R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol. 2006; 8(8):877-884.
6. Haupt S, Berger M, Goldberg Z and Haupt Y. Apoptosis-the p53 network. J Cell Sci. 2003; 116(Pt 20):4077-4085.
7. Wang W and El-Deiry WS. Restoration of p53 to limit tumor growth. Curr Opin Oncol. 2008; 20(1):90-96.
8. Downward J. PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol. 2004; 15(2):177-182.
9. Manning BD and Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007; 129(7):1261-1274.
10. Feng Z. p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment. Cold Spring Harb Perspect Biol. 2010; 2(2):a001057.
11. Kleeff J, Kornmann M, Sawhney H and Korc M. Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells. Int J Cancer. 2000; 86(3):399-407.
12. Sobell HM. Actinomycin and DNA transcription. Proc Natl Acad Sci USA. 1985; 82(16):5328-5331.
13. Chen Y, Liu J, Yuan B, Cao C, Qin S, Cao X, Bian G, Wang Z and Jiang J. Methylated actinomycin D, a novel actinomycin D analog induces apoptosis in HepG2 cells through fas-and mitochondria-mediated pathways. Mol Carcinog. 2013; 52(12):983-996.
14. Choong ML, Yang H, Lee MA and Lane DP. Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy. Cell Cycle. 2009; 8(17):2810-2818.
15. van Leeuwen IM, Higgins M, Campbell J, Brown CJ, McCarthy AR, Pirrie L, Westwood NJ and Lain S. Mechanism-specific signatures for small-molecule p53 activators. Cell Cycle. 2011; 10(10):1590-1598.
16. Hietanen S, Lain S, Krausz E, Blattner C and Lane DP. Activation of p53 in cervical carcinoma cells by small molecules. Proc Natl Acad Sci USA. 2000; 97(15):8501-8506.
17. Rao B, Lain S and Thompson AM. p53-Based cyclotherapy: exploiting the 'guardian of the genome' to protect normal cells from cytotoxic therapy. Br J Cancer. 2013; 109(12):2954-2958.
18. van Leeuwen IM. Cyclotherapy: opening a therapeutic window in cancer treatment. Oncotarget. 2012; 3(6):596-600.
19. Zhang Y, Wolf GW, Bhat K, Jin A, Allio T, Burkhart WA and Xiong Y. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol Cell Biol. 2003; 23(23):8902-8912.
20. Miliani de Marval PL and Zhang Y. The RP-Mdm2-p53 pathway and tumorigenesis. Oncotarget. 2011; 2(3):234-238.
21. Lohrum MA, Ludwig RL, Kubbutat MH, Hanlon M and Vousden KH. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell. 2003; 3(6):577-587.
22. Holzel M, Burger K, Muhl B, Orban M, Kellner M and Eick D. The tumor suppressor p53 connects ribosome biogenesis to cell cycle control: a double-edged sword. Oncotarget. 2010; 1(1):43-47.
23. Toledo F and Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer. 2006; 6(12):909-923.
24. Wu GS. The functional interactions between the p53 and MAPK signaling pathways. Cancer Biol Ther. 2004; 3(2):156-161.
25. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997; 88(3):323-331.
26. Vasudevan KM and Garraway LA. AKT signaling in physiology and disease. Curr Top Microbiol Immunol. 2010; 347:105-133.
27. Liao Y and Hung MC. Physiological regulation of Akt activity and stability. Am J Transl Res. 2010; 2(1):19-42.
28. Mayo LD and Donner DB. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci. 2002; 27(9):462-467.
29. Gottlieb TM, Leal JF, Seger R, Taya Y and Oren M. Crosstalk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene. 2002; 21(8):1299-1303.
30. Kim SJ, Hwang SG, Shin DY, Kang SS and Chun JS. p38 kinase regulates nitric oxide-induced apoptosis of articular chondrocytes by accumulating p53 via NFkappa B-dependent transcription and stabilization by serine 15 phosphorylation. J Biol Chem. 2002; 277(36):33501-33508.
31. Zhu Y, Mao XO, Sun Y, Xia Z and Greenberg DA. p38 Mitogen-activated protein kinase mediates hypoxic regulation of Mdm2 and p53 in neurons. J Biol Chem. 2002; 277(25):22909-22914.
32. Su JG, Liao PJ, Huang MC, Chu WC, Lin SC and Chang YJ. Aldo-keto reductase 1C2 is essential for 1-nitropyrene's but not for benzo[a]pyrene's induction of p53 phosphorylation and apoptosis. Toxicology. 2008; 244(2-3):257-270.
33. Cheng WH, Zheng X, Quimby FR, Roneker CA and Lei XG. Low levels of glutathione peroxidase 1 activity in selenium-deficient mouse liver affect c-Jun N-terminal kinase activation and p53 phosphorylation on Ser-15 in pro-oxidant-induced aponecrosis. Biochem J. 2003; 370(Pt 3):927-934.
34. Sablina AA, Chumakov PM, Levine AJ and Kopnin BP. p53 activation in response to microtubule disruption is mediated by integrin-Erk signaling. Oncogene. 2001; 20(8):899-909.
35. She QB, Bode AM, Ma WY, Chen NY and Dong Z. Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase. Cancer Res. 2001; 61(4):1604-1610.
36. Rasul A, Ding C, Li X, Khan M, Yi F, Ali M and Ma T. Dracorhodin perchlorate inhibits PI3K/Akt and NF-kappaB activation, up-regulates the expression of p53, and enhances apoptosis. Apoptosis. 2012; 17(10):1104-1119.
37. Park S, Kim D, Dan HC, Chen H, Testa JR and Cheng JQ. Identification of an Akt interaction protein, PHF20/TZP, that transcriptionally regulates p53. J Biol Chem. 2012; 287:11151-11163.
38. Weng JR, Bai LY, Chiu CF, Wang YC and Tsai MH. The dietary phytochemical 3,3'-diindolylmethane induces G2/M arrest and apoptosis in oral squamous cell carcinoma by modulating Akt-NF-kappaB, MAPK, and p53 signaling. Chem Biol Interact. 2012; 195(3):224-230.
39. Dung TD, Day CH, Binh TV, Lin CH, Hsu HH, Su CC, Lin YM, Tsai FJ, Kuo WW, Chen LM and Huang CY. PP2A mediates diosmin p53 activation to block HA22T cell proliferation and tumor growth in xenografted nude mice through PI3K-Akt-MDM2 signaling suppression. Food Chem Toxicol. 2012; 50(5):1802-1810.
40. Manfe V, Biskup E, Rosbjerg A, Kamstrup M, Skov AG, Lerche CM, Lauenborg BT, Odum N and Gniadecki R. miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma. PLoS One. 2012; 7(1):e29541.
41. Lee KB, Byun HJ, Park SH, Park CY, Lee SH and Rho SB. CYR61 controls p53 and NF-kappaB expression through PI3K/Akt/mTOR pathways in carboplatin-induced ovarian cancer cells. Cancer Lett. 2012; 315(1):86-95.
42. Ji H, Ding Z, Hawke D, Xing D, Jiang BH, Mills GB and Lu Z. AKT-dependent phosphorylation of Niban regulates nucleophosmin-and MDM2-mediated p53 stability and cell apoptosis. EMBO Rep. 2012; 13(6):554-560.
43. Del Sal G, Murphy M, Ruaro E, Lazarevic D, Levine AJ and Schneider C. Cyclin D1 and p21/waf1 are both involved in p53 growth suppression. Oncogene. 1996; 12(1):177-185.
44. Boehme KA, Kulikov R and Blattner C. p53 stabilization in response to DNA damage requires Akt/PKB and DNA-PK. Proc Natl Acad Sci USA. 2008; 105(22):7785-7790.
45. Astle MV, Hannan KM, Ng PY, Lee RS, George AJ, Hsu AK, Haupt Y, Hannan RD and Pearson RB. AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy. Oncogene. 2012; 31(15):1949-1962.
46. Rao B, van Leeuwen IM, Higgins M, Campbel J, Thompson AM, Lane DP and Lain S. Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Oncotarget. 2010; 1(7):639-650.
47. van Leeuwen IM, Rao B, Sachweh MC and Lain S. An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells. Cell Cycle. 2012; 11(9):1851-1861.
48. Huang MC, Chen FY, Chou MT and Su JG. Fluoranthene enhances p53 expression and decreases mutagenesis induced by benzo[a]pyrene. Toxicol Lett. 2012; 208(3):214-224.